S&P 500
7,757.17
+44.60
+0.58%
Dow
52,856.10
+360.20
+0.69%
Nasdaq
26,702.86
+278.04
+1.05%
NYSE Composite
24,253.12
+62.52
+0.26%
Russell 2000
2,781.02
+7.60
+0.27%
VIX
18.29
+1.61
+9.65%
EDIT · Editas Medicine, Inc.
NASDAQ NMS - GLOBAL MARKET - BOATS Real Time Price • USD
Editas Medicine Inc (EDIT)
NASDAQ NMS - GLOBAL MARKET
Biotechnology
$2.50
-0.08
(-2.91%)
● At close: October 21 at 4:00:00 PM EDT
DAY'S RANGE
$2.50
$2.50
$2.60
52-WEEK RANGE
$2.50
$1.66
$4.28
What's happening
- EDIT is down 2.91% today, trading at $2.50. — Live quote
- Volume today (103,430) is well below its 3-month average of 2,590,180. (Finnhub fundamentals)
- Reports earnings on 2026-11-09, 18 days away. (Finnhub earnings calendar)
- Last quarter's EPS beat estimates: $-0.15 actual vs. $-0.28 estimated (+45.5%). (Finnhub earnings history)
Deterministic template sentences filled in from the same sourced figures shown elsewhere on this page -- not an AI-written summary, no live model call.
Key Statistics
Analyst Recommendations
Strong buy 6
Buy 7
Hold 4
Sell 2
Strong sell 0
Aggregate ratings for 2026-10-01 (19 analysts polled by Finnhub) — consensus count.
Performance Overview (Trailing returns vs S&P 500 benchmark)
YTD RETURN
EDIT
+25.85%
vs S&P 500
+13.08%
1-YEAR RETURN
EDIT
-37.68%
vs S&P 500
-52.24%
6-MONTH RETURN
EDIT
-22.99%
3-MONTH RETURN
EDIT
-10.73%
Earnings Trends (Quarterly EPS Actual vs Estimate)
2026-07-26 (Q2 2026)
$-0.15
Est. $-0.28
BEAT +45.5%
2026-04-26 (Q1 2026)
$-0.26
Est. $-0.27
BEAT +3.3%
2026-01-26 (Q4 2025)
$-0.06
Est. $-0.26
BEAT +77.2%
2025-10-26 (Q3 2025)
$-0.28
Est. $-0.30
BEAT +7.3%
Valuation Measures & Ratios
Enterprise Value4$280.9M
Forward P/E5—
PEG Ratio6—
Price / Sales (TTM1)8.66
Price / Book75.16
EV4 / Revenue5.98
EV4 / EBITDA—
Profit Margin-157.32%
Operating Margin-161.39%
Return on Equity (ROE8)-196.63%
Return on Assets (ROA9)-38.17%
Avg Volume (3M)2,590,180
Quarterly history (5 periods)
| Measure | Jun '26 | Mar '26 | Sep '25 | Jun '25 | Mar '25 |
|---|---|---|---|---|---|
| Market cap | $393.8M | $237.8M | $311.3M | $185.9M | $95.9M |
| P/E | -3.24 | -1.33 | -1.44 | -0.72 | -0.36 |
| Price/Sales | 15.24 | 12.78 | 19.65 | 21.10 | 15.07 |
| Price/Book | 3.74 | 53.95 | 23.14 | 9.69 | 1.54 |
| EV/Revenue | 10.36 | 9.07 | 12.92 | 11.81 | 1.86 |
| ROE | -115.47% | -4070.37% | -1609.91% | -1350.10% | -429.01% |
| ROA | -51.21% | -120.14% | -107.35% | -123.03% | -101.57% |
Trailing-twelve-month ratios computed from SEC EDGAR quarterly figures and historical daily close prices (Alpaca). Diluted shares are derived from Net income ÷ EPS (diluted) for each quarter, not separately reported. Forward P/E/PEG unavailable (no free data source).
Glossary — what these abbreviations mean
- 1. TTM
- Trailing twelve months — the sum of the last four reported quarters, not a calendar year or the single latest quarter.
- 2. EPS
- Earnings per share — net income divided by diluted shares outstanding.
- 3. Beta
- A stock's historical volatility relative to the overall market. Above 1 means it has moved more than the market; below 1, less.
- 4. EV (Enterprise Value)
- Market cap plus total debt minus cash — roughly what it would cost to buy the whole company, debt included.
- 5. Forward P/E
- Price divided by analysts' estimated earnings for the next 12 months, instead of trailing actual earnings.
- 6. PEG Ratio
- P/E divided by expected earnings growth rate. A lower number can indicate a stock is cheap relative to how fast it's expected to grow.
- 7. Price / Book
- Share price divided by book value (assets minus liabilities) per share.
- 8. ROE
- Return on equity — net income divided by shareholders' equity, a measure of how efficiently a company turns equity into profit.
- 9. ROA
- Return on assets — net income divided by total assets, a measure of how efficiently a company turns assets into profit.
- 10. MRQ
- Most recent quarter — the single latest reported period, as opposed to TTM. The Financials section's "Quarterly" view below shows MRQ-style figures.
- 11. YoY
- Year over year — percent change versus the same period one year earlier, used for growth figures like those on Compare cards and the Screener.
Short Interest
Shares Short37,109,260
Change from Prior Settlement+23.85%
% of Float—
Days to Cover (Short Ratio)9.35
Source: FINRA Rule 4560 consolidated short interest, settlement date 2026-09-30. Reported bi-monthly with a reporting lag — not real-time.
Quotes and the 1-day extended-hours chart: Yahoo Finance. Longer historical charts: Alpaca (IEX feed) — real-time but IEX-only volume (~2.5% of consolidated market volume). Fundamentals + earnings: Finnhub.
Price history
Events
Drag horizontally to zoom into a section; use Reset view to restore all observations.
Technical signal summary
Calculating from the latest year of daily price history…
Show Technical Analysis Breakdown ▾ 10 Indicators
Not investment advice — read several signals together.
Indicators None active
Loading chart…
History limited by data provider; markers are heuristics, not signals.
Peer and sector context
No reviewed peer group is available for this symbol.
Balanced evidence
A deterministic summary of sourced facts—not an AI verdict.
Potential strengths
- Revenue growth is 232.3% on the provider's reported measure. Finnhub fundamentals ↗
- Latest SEC filing is Form 8-K, filed 2026-10-08; review it for current changes and risks. SEC EDGAR ↗
Potential concerns
- Net profit margin is -157.3%. Finnhub fundamentals ↗
- Trailing 52-week price return is -37.7%. Finnhub market metrics ↗
Rule-based facts only; absence from either side is not evidence, and this is not a recommendation.
More on EDIT
No accessible free API for these — links go to the source directly.
Financials
Fundamental trends
Visualized from the same SEC figures in the tables below.
Income statement
| Line item | Jun '26 | Mar '26 | Sep '25 | Jun '25 | Mar '25 | Sep '24 | Jun '24 | Mar '24 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $11.9M | $2.8M | $7.5M | $3.6M | $4.7M | $61.0K | $513.0K | $1.1M |
| Operating income | -$18.6M | -$25.0M | -$24.5M | -$51.5M | -$76.2M | -$65.7M | -$71.9M | -$67.0M |
| Net income | -$18.2M | -$25.0M | -$25.1M | -$53.2M | -$76.1M | -$62.1M | -$67.6M | -$62.0M |
| EPS (diluted) | $-0.15 | $-0.26 | $-0.28 | $-0.63 | $-0.92 | $-0.75 | $-0.82 | $-0.76 |
| EPS (basic) | $-0.15 | $-0.26 | $-0.28 | $-0.63 | $-0.92 | $-0.75 | $-0.82 | $-0.76 |
| Operating margin | -$156 | -$883 | -$325 | -$1.4K | -$1.6K | -$107.6K | -$14.0K | -$5.9K |
| Net margin | -$153 | -$882 | -$333 | -$1.5K | -$1.6K | -$101.9K | -$13.2K | -$5.5K |
Balance sheet
| Line item | Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 |
|---|---|---|---|---|---|---|---|---|
| Total assets | $237.4M | $149.3M | $186.5M | $201.8M | $210.6M | $263.7M | $341.6M | $327.6M |
| Total liabilities | $132.1M | $144.9M | $159.2M | $188.3M | $191.4M | $201.2M | $207.3M | $151.9M |
| Stockholders' equity | $105.3M | $4.4M | $27.3M | $13.5M | $19.2M | $62.4M | $134.3M | $175.6M |
| Total current assets | $218.1M | $128.1M | $163.9M | $176.9M | $182.8M | $224.8M | $289.3M | $271.1M |
| Total current liabilities | $68.4M | $39.8M | $46.2M | $61.8M | $65.9M | $73.1M | $77.2M | $72.4M |
| Cash & equivalents | $181.8M | $123.6M | $146.6M | $165.6M | $138.5M | $138.7M | $131.5M | $95.8M |
| Marketable securities (current) | $29.8M | — | $0 | $0 | $40.0M | $82.3M | $138.4M | $169.3M |
| Accounts receivable | $2.7M | $2.6M | $15.2M | $8.1M | $588.0K | $510.0K | $16.3M | $126.0K |
| Marketable securities (non-current) | — | — | — | — | — | — | $0 | $0 |
| Property, plant & equipment | $2.6M | $2.9M | $3.5M | $4.3M | $4.6M | $8.2M | $14.5M | $15.4M |
| Other non-current assets | $3.0M | $3.0M | $3.0M | $3.0M | $4.2M | $4.2M | $5.2M | $5.3M |
| Accounts payable | $4.7M | $4.3M | $2.6M | $3.2M | $6.7M | $5.5M | $5.5M | $12.5M |
| Accrued liabilities | $17.4M | $21.2M | $32.6M | $47.5M | $48.1M | $47.5M | $45.9M | $28.8M |
| Deferred revenue (current) | $32.3M | — | $0 | $0 | $0 | $2.0M | $6.2M | $14.7M |
| Short-term debt | $7.5M | $7.5M | $5.0M | $5.0M | $5.0M | $5.0M | $5.0M | — |
| Other current liabilities | — | — | — | — | — | — | — | — |
| Long-term debt | $48.2M | $47.2M | $53.6M | $54.1M | $51.7M | $49.6M | $52.4M | — |
| Other non-current liabilities | $2.4M | $2.9M | $2.8M | $4.7M | $4.6M | $6.4M | $3.1M | $3.3M |
| Common stock & paid-in capital | $15.0K | $10.0K | $10.0K | $9.0K | $9.0K | $8.0K | $8.0K | $8.0K |
| Retained earnings | -$1.67B | -$1.65B | -$1.63B | -$1.62B | -$1.60B | -$1.54B | -$1.47B | -$1.42B |
| Accumulated other comprehensive income (loss) | -$6.0K | $0 | $0 | $0 | $15.0K | $88.0K | $268.0K | $522.0K |
Cash flow
| Line item | Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$29.6M | -$23.1M | -$36.4M | -$30.8M | -$50.2M | -$47.8M | -$50.8M | -$52.6M |
| Investing cash flow | -$29.8M | $64.0K | $58.0K | $39.6M | $42.6M | $56.4M | $31.0M | $84.0M |
| Financing cash flow | $117.5M | $0 | $17.3M | $17.2M | $7.4M | -$1.4M | $55.5M | $0 |
| Free cash flow | -$29.7M | -$23.2M | -$36.4M | -$31.3M | -$50.2M | -$47.9M | -$51.3M | -$55.5M |
| Capital expenditures | $106.0K | $92.0K | $60.0K | $433.0K | $0 | $114.0K | $540.0K | $2.9M |
| Share-based compensation | $2.2M | $2.1M | $2.1M | $2.2M | $2.7M | $3.0M | $4.0M | $4.8M |
| Deferred income taxes | — | — | — | — | — | — | — | — |
| Change in accounts receivable | $133.0K | -$12.6M | $7.0M | $7.5M | $78.0K | -$15.8M | $16.1M | -$118.0K |
| Change in accounts payable | -$58.0K | $1.7M | -$558.0K | -$3.6M | $1.3M | -$27.0K | -$7.0M | -$1.3M |
| Purchases of investments | $29.7M | — | $0 | $0 | $0 | $0 | -$4.0K | $0 |
| Debt repaid | — | — | — | — | — | — | — | — |
Income statement
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Revenue | $40.5M | $32.3M | $78.1M | $19.7M | $25.5M |
| Operating income | -$160.0M | -$251.2M | -$169.2M | -$225.9M | -$193.1M |
| Net income | -$160.1M | -$237.1M | -$153.2M | -$220.4M | -$192.5M |
| EPS (diluted) | $-1.80 | $-2.88 | $-2.02 | $-3.21 | $-2.85 |
| EPS (basic) | $-1.80 | $-2.88 | $-2.02 | $-3.21 | $-2.85 |
| Operating margin | -$395 | -$777 | -$217 | -$1.1K | -$756 |
| Net margin | -$395 | -$734 | -$196 | -$1.1K | -$754 |
Balance sheet
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Total assets | $186.5M | $341.6M | $499.2M | $514.3M | $677.5M |
| Total liabilities | $159.2M | $207.3M | $150.1M | $153.6M | $123.8M |
| Stockholders' equity | $27.3M | $134.3M | $349.1M | $360.7M | $553.6M |
| Total current assets | $163.9M | $289.3M | $340.8M | $356.8M | $507.3M |
| Total current liabilities | $46.2M | $77.2M | $63.2M | $60.1M | $46.9M |
| Cash & equivalents | $146.6M | $131.5M | $123.7M | $141.5M | $203.5M |
| Marketable securities (current) | $0 | $138.4M | $199.5M | $202.8M | $296.3M |
| Accounts receivable | $15.2M | $16.3M | $10.2M | $5.1M | $267.0K |
| Marketable securities (non-current) | — | $0 | $104.0M | $93.1M | $120.1M |
| Property, plant & equipment | $3.5M | $14.5M | $12.0M | $15.6M | $17.1M |
| Other non-current assets | $3.0M | $5.2M | $8.6M | $5.3M | $6.8M |
| Accounts payable | $2.6M | $5.5M | $8.3M | $9.5M | $5.0M |
| Accrued liabilities | $32.6M | $45.9M | $34.6M | $31.3M | $20.2M |
| Deferred revenue (current) | $0 | $6.2M | $8.2M | $8.2M | $11.3M |
| Short-term debt | $5.0M | $5.0M | $0 | — | — |
| Other current liabilities | — | — | — | — | — |
| Long-term debt | $53.6M | $52.4M | $0 | — | — |
| Other non-current liabilities | $2.8M | $3.1M | $1.8M | $0 | — |
| Common stock & paid-in capital | $10.0K | $8.0K | $8.0K | $7.0K | $7.0K |
| Retained earnings | -$1.63B | -$1.47B | -$1.23B | -$1.08B | -$857.7M |
| Accumulated other comprehensive income (loss) | $0 | $268.0K | $198.0K | -$3.6M | -$493.0K |
Cash flow
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Operating cash flow | -$165.2M | -$210.3M | -$132.2M | -$177.3M | -$163.8M |
| Investing cash flow | $138.7M | $162.1M | -$3.7M | $114.1M | -$54.5M |
| Financing cash flow | $40.5M | $56.0M | $118.0M | $1.3M | $282.1M |
| Free cash flow | -$165.8M | -$219.1M | -$136.9M | -$181.5M | -$171.8M |
| Capital expenditures | $607.0K | $8.8M | $4.7M | $4.1M | $8.0M |
| Share-based compensation | $10.0M | $21.4M | $19.8M | $29.3M | $43.4M |
| Change in accounts receivable | -$1.1M | $6.1M | $5.0M | $4.9M | -$5.8M |
| Change in accounts payable | -$2.9M | -$2.3M | -$1.5M | $4.4M | -$1.1M |
| Purchases of investments | $0 | $86.2M | $258.5M | $315.2M | $408.9M |
| Debt repaid | — | — | — | — | — |
Source: SEC EDGAR XBRL filings (10-Q/10-K), as originally tagged by the company. Quarterly cash flow is reconstructed by de-cumulating fiscal-year-to-date figures (how cash flow is tagged in 10-Qs); other quarterly lines are reported directly.
Institutional holders
SEC Form 13F filers holding EDIT as of the latest reported quarter. 13F only covers investment managers with $100M+ in assets — this is not a complete ownership picture, and does not include insiders (see Recent SEC filings below) or non-13F-eligible holders.
Institutional ownership is not available for this symbol right now.
Insider activity
Directors, officers, and 10%+ owners' reported transactions from SEC Form 4. A filing reports a transaction; it does not by itself explain why it happened.
Source: SEC EDGAR Form 4 filings · checked 25 most recent filings · covers 2025-09-03 to 2026-09-03
Recent transactions
- Insiders have net sold 28,467 shares over the last 182 days, across 0 purchases and 8 sales.
- Most recent: Burkly Linda (EVP, CHIEF SCIENTIFIC OFFICER) — Open market sale of 709 shares on 2026-09-03.
Deterministic template sentences filled in from the SEC Form 4 figures in the tables below -- not an AI-written summary, no live model call.
Insider purchases & sales, last 6 months
Purchases (open market)0 sh(0 txns)
Sales (open market)28,467 sh(8 txns)
Net Shares-28,467
Counts only open-market purchases (code P) and sales (code S) — grants, option exercises, tax withholding, and gifts are excluded since they aren't a market buy/sell decision.
Insider roster
| Name | Title | Most Recent Transaction | Date | Shares |
|---|---|---|---|---|
| Burkly Linda | EVP, CHIEF SCIENTIFIC OFFICER | Open market sale | 2026-09-03 | 709 |
| Parison Amy | SVP, Chief Financial Officer | Open market sale | 2026-09-03 | 453 |
| O'Neill Gilmore Neil | CEO | Open market sale | 2026-09-03 | 5,124 |
Recent transactions
| Date | Insider | Title | Transaction | Shares | Price |
|---|---|---|---|---|---|
| 2026-09-03 | Burkly Linda | EVP, CHIEF SCIENTIFIC OFFICER | Open market sale | 709 | $3.04 |
| 2026-09-03 | Parison Amy | SVP, Chief Financial Officer | Open market sale | 453 | $3.04 |
| 2026-09-03 | O'Neill Gilmore Neil | CEO | Open market sale | 5,124 | $3.04 |
| 2026-08-03 | Parison Amy | SVP, Chief Financial Officer | Open market sale | 678 | $2.58 |
| 2026-07-28 | Burkly Linda | EVP, CHIEF SCIENTIFIC OFFICER | Open market sale | 4,928 | $2.67 |
| 2026-06-03 | Parison Amy | SVP, Chief Financial Officer | Open market sale | 464 | $2.70 |
| 2026-06-03 | O'Neill Gilmore Neil | CEO | Open market sale | 15,380 | $2.70 |
| 2026-06-03 | Burkly Linda | EVP, CHIEF SCIENTIFIC OFFICER | Open market sale | 731 | $2.70 |
| 2026-03-03 | O'Neill Gilmore Neil | CEO | Open market sale | 5,394 | $2.02 |
| 2026-03-03 | Parison Amy | SVP, Chief Financial Officer | Open market sale | 474 | $2.02 |
| 2026-03-03 | Burkly Linda | EVP, CHIEF SCIENTIFIC OFFICER | Open market sale | 749 | $2.02 |
| 2025-12-03 | Burkly Linda | EVP, CHIEF SCIENTIFIC OFFICER | Open market sale | 713 | $2.15 |
| 2025-12-03 | O'Neill Gilmore Neil | CEO | Open market sale | 5,603 | $2.15 |
| 2025-12-03 | Parison Amy | SVP, Chief Financial Officer | Open market sale | 461 | $2.15 |
| 2025-09-03 | Burkly Linda | EVP, CHIEF SCIENTIFIC OFFICER | Open market sale | 710 | $2.60 |
Recent SEC filings
Official company reports and insider transaction filings. Form 4 reports a transaction; it does not by itself explain why it happened.
Source: SEC EDGAR submissions · updated 2026-10-22 07:31 UTC
| Filed | Form | Report period | Official filing |
|---|---|---|---|
| 2026-10-08 | 8-K | 2026-10-08 | View on SEC.gov → |
| 2026-09-09 | 4 | 2026-09-08 | View on SEC.gov → |
| 2026-09-04 | 4 | 2026-09-03 | View on SEC.gov → |
| 2026-09-04 | 4 | 2026-09-03 | View on SEC.gov → |
| 2026-09-04 | 4 | 2026-09-03 | View on SEC.gov → |
| 2026-08-07 | 4 | 2026-08-06 | View on SEC.gov → |
| 2026-08-05 | 4 | 2026-08-03 | View on SEC.gov → |
| 2026-08-05 | 10-Q | 2026-06-30 | View on SEC.gov → |
| 2026-08-05 | 8-K | 2026-08-03 | View on SEC.gov → |
| 2026-07-29 | 4 | 2026-07-28 | View on SEC.gov → |
| 2026-06-22 | 4 | 2026-06-17 | View on SEC.gov → |
| 2026-06-22 | 4 | 2026-06-17 | View on SEC.gov → |
Recent news
Headlines about EDIT (Editas Medicine, Inc.). Links open the publisher — we don’t host full articles.
-
Mint Quick Edit | SBI data breach: India's AI efforts must make cybersecurity a priority
TradingView · 2026-10-22 -
Saurabh Mukherjea Reveals His Biggest Bets For Samvat 2083 | Stock Market | Investing | Diwali Edit
Livemint · 2026-10-22 -
Jasmine Mitchell Says ‘Great British Baking Show’ Editors Left Out One Surprising Moment From Her Season
Parade Magazine · 2026-10-21 -
Zales Goes the Distance With The 26.2 Edit, a Curated Jewelry Collection Made to Move With You Through Every Mile
Yahoo Finance · 2026-10-21 -
Mint Quick Edit | Is AI hype finally fizzling out? Here’s what global equity market trends suggest
Livemint · 2026-10-21 -
Why Should You Think About Vertex Differently Now?
Yahoo · 2026-10-21 -
Wells Fargo raises target for Editas Medicine stock from USD 4.00 to USD 6.00 - ad-hoc-news.de
ad-hoc-news.de · 2026-10-20 -
Brothers Osborne preview upcoming ‘Watertown’ album with “Doors (Sellout Edit)”
100.3 The Wolf · 2026-10-19
No headlines in this category right now — try “All”.